Acute Lymphoblastic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Conditions: Acute Lymphoblastic Leukemia, Pediatric Interventions: Drug: Dasatinib(Sprycel) arm; Drug: Non-Dasatinib(Sprycel) arm Sponsors: Hyoung Jin Kang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Conditions: Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Interventions: Drug: KTE-X19; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: Kite, A Gilead Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)
Conditions: Cancer Interventions: Drug: Lenalidomide Sponsors: University Hospital, Caen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation
Conditions: Very High Risk Acute Lymphoblastic Leukemia; CD19 CAR-T Therapy Interventions: Genetic: SNUH-CD19-CAR-T Sponsors: Seoul National University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials

Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
Conditions: Acute Lymphoblastic Leukemia; Thrombosis; Bleeding; Hemostatic Disorder Interventions: Diagnostic Test: Coagulopathy parameters Sponsors: Karolinska University Hospital; Karolinska Institutet Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients
Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma Interventions: Drug: blinatumomab for B-ALL, venetoclax for T-ALL Sponsors: National Research Center for Hematology, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Conditions: Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma Interventions: Biological: Anti-CD19 CAR-T cells Sponsors: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Conditions: Acute Lymphoblastic Leukemia; Philadelphia Chromosome; Philadelphia-Positive ALL; Adult ALL; IKZF1 Gene Mutation Interventions: Drug: Prednisone, Olverembatinib, Blinatumomab, Chidamide Sponsors: Nanfang Hospital, Southern Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
Conditions: B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma Refractory Interventions: Drug: Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells Sponsors: Wuhan Union Hospital, China; CSPC Pharmaceutical Group Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

This Phase I/II Trial Assesses Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphomas (PMBCL/CNS-BCL). It Explores Safety, Efficacy, and Simplifying Cell Production, Enrolling Patients From Multiple Centers
Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCL Interventions: Biological: CD19/CD22-CAR T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCL Interventions: Biological: CD19/CD22-CAR T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01
IRVINE, Calif., Jan. 18, 2024. PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 18, 2024 Category: Pharmaceuticals Source Type: clinical trials

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
Conditions: T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Drug: Calaspargase Pegol; Procedure: Computed Tomography; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin; Drug: Dexamethasone; Drug: Doxorubicin; Procedure: Echocardiography; Procedure: Lumbar Puncture; Drug: Mercaptopurine; Drug: Methotrexate; Procedure: Multigated Acquisition Scan; Biological: Navitoclax; Drug: Nelarabine; Drug: Pegaspargase; Procedure: Positron Emission Tomography; Drug: Thioguanine; Drug: Venetoclax; Drug: ...
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation
Conditions: Acute Lymphoblastic Leukemia Interventions: Radiation: total marrow and total lymphoid irradiation Sponsors: Hospital Universitario Dr. Jose E. Gonzalez Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Conditions: B-Cell Leukemia; Non-Hodgkin ' s Lymphoma; B-cell Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); Mantle Cell Lymphoma; B-cell Lymphoma Interventions: Biological: CLIC-2201 Sponsors: British Columbia Cancer Agency Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials